India Resurgence Fund (IndiaRF), promoted by Piramal Enterprises Limited and Bain Capital on Wednesday said, It will be acquiring API & CRAMS business from Ind-Swift laboratories for Rs 1,650 crores.
IndiaRF in its press release said, “The Board of Directors of Ind-Swift Laboratories Limited (Ind-Swift) on September 6th, 2023 approved a business transfer of its active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs Private Limited (Synthimed), a portfolio company of India Resurgence Fund (IndiaRF). IndiaRF, a leading India-focused investment platform promoted by Piramal Enterprises Limited and Bain Capital, will acquire the business for a consideration of INR 1,650 crores.”
Ind-Swift is among the top ten independent merchant API businesses in India in size, with two manufacturing sites in Punjab and Jammu, and a combined reactor capacity of ~700 KL catering to both regulated and unregulated markets. The API business has a strong market and cost position with a diverse therapeutic presence across the US, Japan, Korea, EU, Brazil, and India. Ind-Swift reported consolidated revenue of INR 1,207 Cr and consolidated EBITDA of INR 256 Cr in FY23.
“Shareholder and regulatory approvals are required for the completion of the transaction. Synthimed will also acquire an intermediate manufacturing facility from the promoter group,” the company said.
Commenting on the transaction, Shantanu Nalavadi, Managing Director of IndiaRF, said, “IndiaRF is excited about the transformation potential of Ind-Swift. Ind-Swift has a strong market presence and a competitive cost position. We believe the business needs the necessary capital infusion for it to acquire scale and move upwards in its growth trajectory. We are committed to investing further primary capital into the businesses to expand capacity on the back of growth from new geographies and investment in new product development across both API and CRAMS, to provide a larger portfolio of products to its customers.”
“Ind-Swift is among the largest independent API players in India and has had a track record of developing API molecules with a customer-centric approach and has created high-quality facilities. We are delighted that IndiaRF, which has a pedigree and track record of transforming businesses across varied sectors, will support and invest in the growth of the business. We are grateful to our team and wish them the best to scale the business to new heights under IndiaRF’s stewardship,” N R Munjal, Chairman and Managing Director of Ind-Swift further added.
